2020
DOI: 10.1590/0102-672020200002e1522
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Cert… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(20 citation statements)
references
References 17 publications
(20 reference statements)
0
1
0
1
Order By: Relevance
“…O infliximabe reduziu o processo inflamatório mucoso e a infiltração de células inflamatórias na mucosa e submucosa do cólon excluso 3 . Quando se considera que a terapia biológica, em especial com infliximabe é considerada a opção terapêutica mais eficiente para o tratamento das DII 27 . Sendo assim, é possível que seu uso na CD possa, da mesma forma, reduzir a inflamação e preservar os sistemas de defesa epitelial.…”
Section: Mensagem Centralunclassified
“…Infliximab reduced the mucosal inflammatory process and the infiltration of inflammatory cells in the excluded colonic mucosa and submucosa 3 . By reducing the inflammatory process and favoring the healing of the mucosa, biological therapy, especially infliximab, is considered the most effective therapeutic option for the treatment of IBD 27 . Thus, it is possible that its use in DC can, in the same way, reduce inflammation and preserve epithelial defense systems.…”
Section: Introductionmentioning
confidence: 99%